(CIDRAP News) - The World Health Organization (WHO) recently posted surveillance and status updates for regions where the pandemic H1N1 is just gaining a foothold, including the Mideast, Africa, and parts of Asia and the Pacific, which showed Southeast Asia as the hardest hit of those areas.
(CIDRAP News) A pharmaceutical company is reporting good results in the first clinical trial of an H5N1 avian influenza vaccine that uses a whole, killed H5N1 virus grown in cell culturea combination of techniques that entails some risk but may boost immune response and shorten production time.
(CIDRAP News) A World Health Organization (WHO) working group will meet in Geneva over the next 4 days to try to solve an impasse over how countries share their H5N1 avian influenza virus samples, a disagreement that pits developing countries' demand for affordable vaccines against the global need to monitor virus changes and develop pandemic vaccines.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) Indonesian officials said today they have sent a sample from a recent victim of H5N1 influenza to the World Health Organization (WHO), apparently ending the country's prolonged withholding of H5N1 samples.
(CIDRAP News) – Low doses of a cell-based avian flu vaccine triggered a good immune response to the H5N1 avian influenza virus, according to preliminary results of a clinical trial by Baxter International of Deerfield, Ill., maker of the vaccine.